Increased p53 immunopositivity in anaplastic medulloblastoma and supratentorial PNET is not caused by JC virus by Eberhart, Charles G et al.
BioMed  Central
Page 1 of 8
(page number not for citation purposes)
BMC Cancer
Open Access Research article
Increased p53 immunopositivity in anaplastic medulloblastoma and 
supratentorial PNET is not caused by JC virus
Charles G Eberhart*1, Aneeka Chaudhry1, Richard W Daniel2, Leila Khaki1, 
Keerti V Shah3 and Patti E Gravitt2
Address: 1Department of Pathology, Johns Hopkins University School of Medicine, Ross Bldg 558, 720 Rutland Ave, Baltimore, MD 21205, USA, 
2Department of Epidemiology, The Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe St., Room E6535 Baltimore, MD 21205, 
USA and 3Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, 615 North Wolfe Street, 
Baltimore, MD 21205, USA
Email: Charles G Eberhart* - ceberha@jhmi.edu; Aneeka Chaudhry - achaudh2@jhmi.edu; Richard W Daniel - rdaniel@jhsph.edu; 
Leila Khaki - khaki_le@yahoo.com; Keerti V Shah - kvshah@jhsph.edu; Patti E Gravitt - pgravitt@jhsph.edu
* Corresponding author    
Abstract
Background: p53 mutations are relatively uncommon in medulloblastoma, but abnormalities in
this cell cycle pathway have been associated with anaplasia and worse clinical outcomes. We
correlated p53 protein expression with pathological subtype and clinical outcome in 75 embryonal
brain tumors. The presence of JC virus, which results in p53 protein accumulation, was also
examined.
Methods: p53 protein levels were evaluated semi-quantitatively in 64 medulloblastomas, 3 atypical
teratoid rhabdoid tumors (ATRT), and 8 supratentorial primitive neuroectodermal tumors
(sPNET) using immunohistochemistry. JC viral sequences were analyzed in DNA extracted from
33 frozen medulloblastoma and PNET samples using quantitative polymerase chain reaction.
Results:  p53 expression was detected in 18% of non-anaplastic medulloblastomas, 45% of
anaplastic medulloblastomas, 67% of ATRT, and 88% of sPNET. The increased p53
immunoreactivity in anaplastic medulloblastoma, ATRT, and sPNET was statistically significant. Log
rank analysis of clinical outcome revealed significantly shorter survival in patients with p53
immunopositive embryonal tumors. No JC virus was identified in the embryonal brain tumor
samples, while an endogenous human retrovirus (ERV-3) was readily detected.
Conclusion: Immunoreactivity for p53 protein is more common in anaplastic medulloblastomas,
ATRT and sPNET than in non-anaplastic tumors, and is associated with worse clinical outcomes.
However, JC virus infection is not responsible for increased levels of p53 protein.
Background
The current World Health Organization classification for
tumors of the nervous system includes medulloblastoma,
medulloepithelioma, ependymoblastoma, supratentorial
primitive neuroectodermal tumor (sPNET) and atypical
teratoid/rhabdoid tumor (ATRT) in the category of embry-
onal brain neoplasms [1]. These tumors are united by
their primitive cytological appearance and the ability to
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differentiate into multiple cell types. However, recent
studies indicate that these lesions are genetically, and to
some extent clinically, separable. ATRT are defined by the
presence of rhabdoid cells, contain INI1 mutations, and
cause particularly grim clinical outcomes [2]. Medullob-
lastomas commonly contain isochromosome 17q, but
this chromosomal alteration is rarely detected in sPNET or
ATRT [3]. Global gene expression profiles also suggest that
medulloblastoma, sPNET and ATRT are distinct entities
[4].
Little is known about the differences in p53 expression
and function among the various embryonal brain tumor
subtypes. Initial reports on the p53 tumor suppressor
gene suggested it was mutated in 10% or less of medullob-
lastomas [5-8]. However, Frank and colleagues have
recently shown that the p53 pathway is inactivated by
mutation of p53, methylation of p14ARF, or deletion of
INK4/ARF in 21% of medulloblastomas [9]. In their
study, 5 of the 6 medulloblastomas with alterations abro-
gating p53 function had significant anaplasia. Large cell/
anaplastic changes in medulloblastoma are prognostic of
significantly worse clinical outcomes [10-12]. Interest-
ingly, p53 protein accumulation, which is often associ-
ated with loss of functionality, has been found by some
[13-15], but not others [16,17], to predict shorter survival
in medulloblastoma patients as well.
Several other lines of evidence also support a role for the
p53 pathway in medulloblastomas. First, medulloblasto-
mas sometimes arise in the context of Li Fraumeni syn-
drome, in which p53 germline mutations predispose
patients to a wide range of neoplasms [18]. Second, inac-
tivation of p53 accelerates the formation of medulloblas-
tomas in transgenic mouse models [19]. Finally,
inactivation of p53 and Rb simultaneously, either through
genetic disruption or overexpression of viral T antigen,
results in medulloblastomas in rodents [20-22].
It has been suggested that viral infection of human CNS
tissues could promote formation of brain tumors by
inhibiting p53 and Rb activity [23]. Some researchers have
reported the presence of JC virus or other oncogenic poly-
omaviruses in human brain tumor specimens, including
medulloblastomas [24,25]. Large T antigen expressed by
these viruses binds and inactivates p53 [26]. This process
results in the accumulation and immunohistochemical
detection of p53 protein. In human neural tissue this is
best demonstrated in progressive multifocal leukoen-
cephalopathy, in which JC virus infected oligodendroglial
cells are strongly p53 immunopositive [27,28]. It is there-
fore possible that the accumulation of p53 protein in
some human medulloblastomas is caused by viral
infection.
In order to confirm the association between p53 immuno-
positivity, clinical outcome, and embryonal tumor sub-
type, we stained a tissue array containing representative
cores from 80 embryonal brain tumors for p53. We also
investigated JC virus infection as a possible mechanism
for accumulation of p53 protein by searching for viral
sequences using a highly sensitive quantitative real time
polymerase chain reaction (PCR) assay. We found an
association between p53 immunoreactivity, clinical out-
come, and tumor subtype, but did not detect JC virus in
medulloblastoma or supratentorial PNET.
Methods
Clinical material
Medulloblastomas and other embryonal brain tumors
diagnosed at the Johns Hopkins University Department of
Pathology were identified through review of departmental
records. Classic, desmoplastic/nodular and large cell/ana-
plastic medulloblastomas were classified using World
Health Organization guidelines [1]. Nuclear size, cell
morphology and the frequency of mitosis and apoptosis
were used as previously described to grade anaplasia [11].
80 Tumors from 78 patients were used to create a tissue
array as previously described [29]. Patients ranged from 8
months to 55 years of age, with a median age of 9 years.
Microscopic examination of the array confirmed that the
appearance of tumor tissue cores corresponded to donor
blocks. Frozen tumor tissue obtained from medulloblast-
omas resected at the Johns Hopkins Hospital was snap-
frozen in liquid nitrogen and stored at minus 80°C prior
to nucleic acid extraction. DNA was extracted using Trizol
and further purified using a DNeasy column (Qiagen,
Valencia, CA) according to the manufacturer's instruc-
tions. This study was approved by the Johns Hopkins Uni-
versity Institutional Review Board.
Immunohistochemistry
The tissue array was sectioned at four microns, deparaffi-
nized, and subjected to antigen retrieval by steaming (20
minutes at 80°C). Slides were then incubated at room
temperature for 45 minutes with monoclonal antibody
directed towards p53 (1:2000, clone DO-7, DAKO,
Carpinteria, CA). Primary antibody was detected using the
avidin-biotin complex (ABC) method with diaminoben-
zadine serving as the chromagen. We semiquantitatively
graded staining intensity as negative, weak, or strong. Car-
cinomas with mutations leading to p53 stabilization were
used as positive controls. No staining was seen in the
absence of primary antibody (negative control).
Detection of virus by real time PCR
JC virus sequences were amplified from DNA using the
forward primer PEP-1 (5'-AGT CTT TAG GGT CTT CTA
CC-3') and reverse primer PEP-2 (5'-GCC AAC CTA TGG
AAC AG-3') [30]. Additional specificity for detection of JCBMC Cancer 2005, 5:19 http://www.biomedcentral.com/1471-2407/5/19
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virus was achieved using the FAM/Black Hole Quencher-1
(FAM/BHQ-1) labeled TaqMan probe (5-/56-FAM/ CCA
ACA CTC TAC CCC ACC T /3BHQ_1/-3) [31]. This probe
does not cross-react to the closely related human BK poly-
omavirus, or simian SV40 polyomavirus. Fifty microliter
reaction volumes were used, comprised of 1X universal
master mix (Applied Biosystems, Foster City, CA), 0.05
µM probe, 0.4 µM PEP-1, 0.4 µM PEP-2, and 16–288 ng
tumor DNA. Amplifications were performed using a Bio-
rad ICycler with the following thermal profile: 95°C for
10 minutes, then 50 cycles at 95°C for 15 seconds and
57°C for 1 minute. Quantitation of JC virus in tumors was
determined using linear regression with an external stand-
ard curve included on each plate containing a 5-fold dilu-
tion series of known input JC virus plasmid diluted in a
constant background of human placental DNA (70 ng/
µl). To normalize for sampling variability, we quantitated
the total cell equivalents in each sample by amplifying a
human endogenous retrovirus gene (ERV-3) in an equal
amount of tumor DNA [32]. Conditions for ERV-3 ampli-
fication were: 0.4 µM forward primer (PHP10-F: 5'-CAT
GGG AAG CAA GGG AAC TAA TG-3'), 0.4 µM reverse
primer (PHP10-R: 5'-CCC AGC GAG CAA TAC AGA ATT
T-3'), and 0.25 µM TaqMan probe labeled with FAM and
BHQ (PHP-P505/ERV-3 Probe: 5'-/56-FAM/TCT TCC
CTC GAA CCT GCA CCA TCA AGT CA/3BHQ_1/-3').
ERV-3 amplification was performed on an ABI 5700 using
the following thermal profile: 95°C for 10 minutes, fol-
lowed by 50 cycles of amplification at 95°C for 15 sec-
onds and 60°C for 30 seconds. DNA extracted from the
diploid cell line ATCC CCL 205 diluted in a constant
background of 50 ng/µl salmon sperm DNA was used to
construct the ERV-3 standard dilution curve.
Statistical analysis
p53 statistical analyses were performed using GraphPad
PRISM4 software (GraphPad Software, San Diego, CA). A
two tailed Fishers Exact test was used to compare immu-
nohistochemical staining profiles between groups. Signif-
icance of survival differences was assessed using log-rank
analysis of Kaplan-Meier curves. The formula 1-(alpha)1/N
was used to calculate the fiducial (exact) 95% upper
bound of JC virus prevalence.
Results
p53 protein levels are increased in anaplastic 
medulloblastoma, ATRT and sPNET
We used immunohistochemistry to examine p53 protein
expression in representative cores from 80 embryonal
brain tumors on a tissue array. Cores from 5 of the cases
could not be evaluated due to crush artefact, cautery, or
low cellularity. Of the remaining 75 tumors, 64 were
medulloblastomas; 31 of these medulloblastoma were of
the classic subtype, 13 were nodular/desmoplastic, and 20
were large cell/anaplastic. The tissue array used in this
study also contained 11 other CNS embryonal tumors,
including 8 sPNET and 3 ATRT. Among the sPNET were 3
with the long epithelial surfaces characteristic of
medulloepithelioma.
Immunoreactivity for p53 was present in a minority
(35%) of the 75 embryonal tumors, and a relatively small
subset of cells stained in most of the positive cases. In all
positive cases the majority of the immunoreactivity was in
tumor cell nuclei. An example of a nodular medulloblast-
oma with weak, scattered p53 immunoreactivity is shown
in Figure 1A. A medulloblastomas and a sPNET with
strong immunoreactivity are shown in Figure 1B and 1C,
respectively. Only 16% (5/31) of classic medulloblasto-
mas and 23% (3 /13) of nodular medulloblastomas were
immunopositive for p53, and staining was weak in all of
these cases. In contrast, 45% (9/20) of anaplastic medul-
loblastomas, 67% (2/3) of ATRT, and 88% (7/8) of sPNET
were positive for p53. The intensity of staining in the ana-
plastic medulloblastomas and extracerebellar embryonal
tumors was strong in many cases (Figure 2). The increase
in p53 immunoreactivity in anaplastic medulloblastomas
was statistically significant when compared to non-ana-
plastic ones, including classic and nodular lesions (P =
0.03, Fisher's Exact test). Other embryonal tumors (sPNET
and ATRT) also had a significant increase in p53 expres-
sion compared to non-anaplastic medulloblastoma (P =
0.0001, Fisher's exact test). p53 expression was often
widespread in the severely anaplastic medulloblastoma,
ATRT, and sPNET groups, with 6 of 12 tumors showing
immunoreactivity in over 25% of cells, while classic and
nodular medulloblastomas always had fewer than 25%
immunopositive cells (Table 1). Staining for p53 was dis-
tributed evenly in most lesions, rather than being concen-
trated in focal groups of tumor cells.
p53 Immunopositivity is significantly associated with worse 
clinical outcomes
We next examined whether p53 immunopositivity was
associated with worse clinical outcomes in embryonal
brain tumor patients. Of the 75 tumors from 73 patients
scored on the array, survival data was available for 66
individuals. 61 percent of patients were alive at last con-
tact, with follow up times ranging from 3 to 215 months
(median 47 months). When survival of the entire embry-
onal brain tumor cohort was analyzed, 67% (31/46) of
patients with p53 immunonegative tumors were alive, as
compared to 45% (9/20) of patients with immunoposi-
tive tumors. Log rank analysis of Kaplan Meier survival
curves confirmed the significance of this difference (P =
0.02). When only the 56 medulloblastoma patients with
clinical follow up were analyzed, 71% of individuals with
p53 negative tumors survived, compared to 58% of indi-
viduals with p53 positive tumors. However, these differ-
ences were not significant on log rank analysis (P = 0.25).BMC Cancer 2005, 5:19 http://www.biomedcentral.com/1471-2407/5/19
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The 6 patients with intensely immunoreactive tumors (3
anaplastic medulloblastoma, 2 sPNET, 1 ATRT) all died
from their disease in less than two years.
JC virus infection does not account for increased levels of 
p53 protein
To address the possibility that p53 accumulation in
medulloblastoma and other embryonal brain tumors is
due to viral infection, we used quantitative RT PCR to
search for viral sequences in tumor DNA. Of the cases
used on the tissue array, 19 had material frozen suitable
for high-quality DNA extraction. Four of these cases were
p53 positive. Also available in our frozen tumor bank was
tissue from 14 additional embryonal lesions (4 classic
medulloblastoma, 5 anaplastic medulloblastoma, 1 nod-
ular medulloblastoma and 4 sPNET). We did not detect JC
virus sequences in any of these 33 tumors. We repeated
the analysis on DNA extracted from a different tumor tis-
sue fragment in 5 cases, but these spatially distinct regions
also failed to contain viral DNA. ERV-3, an endogenous
p53 Immunostaining in CNS embryonal tumors Figure 1
p53 Immunostaining in CNS embryonal tumors. Most 
p53 immunopositivity was relatively faint and present only in 
a small fraction of the tumor. This nodular medulloblastoma 
had weak staining in less than 25% of cells (A). Some anaplas-
tic medulloblastomas had strong p53 immunostaining in a 
larger fraction of cells (B). Most AT/RT and supratentorial 
PNET contained p53 immunopositive cells, like this lesion 
metastatic within the CNS in which almost all cells are 
strongly positive (C). Note the lack pf staining in non-neo-
plastic stroma (Asterisk).
!
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A statistically significant increase in p53 immunopositivity in  AT/RT and sPNET Figure 2
A statistically significant increase in p53 immunopos-
itivity in AT/RT and sPNET Most classic and nodular 
medulloblastoma (MB) contained no p53 immunopositive 
cells. In contrast, p53 positive cells were present in many 
anaplastic MB, supratentorial primitive neuroectodermal 
tumors (sPNET) and atypical teratoid rhabdoid tumors 
(ATRT). Triangles represent individual tumors with negative 
(0), weak (1) or strong (2) p53 immunostaining. Bars repre-
sent the mean and standard error of the mean. The increase 
in p53 immunopositivity in the sPNET/ATRT category as 
compared to classical MB was statistically significant (Mann 
Whitney test).BMC Cancer 2005, 5:19 http://www.biomedcentral.com/1471-2407/5/19
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human retroviral element, served as a control and was eas-
ily amplified from tumor DNA samples (Figure 3). ERV-3
copy numbers ranged from ~2 × 103 - 2 × 105 per PCR
assay (mean 3.4 × 104). Because two copies of ERV-3 are
present per human genome, DNA from at least 1000 cells
was assayed in each PCR reaction. In contrast, all of the
specimens tested were completely negative for JC virus.
The quantitative Taqman assay was able to detect a mini-
mum of ~10 copies of JC virus per PCR reaction as deter-
mined using a standard dilution curve. Thus the number
of JC virus genomes should not exceed 10 per 1,000
tumor cells. Given our 0% detection rate, the 95% confi-
dence limit for the largest value of the 'true' underlying JC
virus prevalence is no more than 7.6% (1-(0.05)1/38).
Discussion
To investigate the prognostic potential and pathological
role of p53 expression in embryonal brain tumors, we
analyzed this protein in 75 medulloblastoma, ATRT and
sPNET using immunohistochemistry. Overall, we found
significant increases in p53 immunoreactivity in
anaplastic medulloblastomas (45% positive) as com-
pared to non-anaplastic ones (18% positive). The percent-
age of p53 immunopositive medulloblastomas in our
study (27%) fell within the previously reported range of
3% to 53% [13,16,17,33,34]. This wide variation in pub-
lished values is likely due to differences in antibodies
used, their dilutions, and antigen retrieval protocols. Cut-
toffs for a calling a tumor "positive" also varied among
previous investigators, with some scoring only intensely
positive lesions. Only 5% of our medulloblastomas fell
into this strong staining category, and all of these were
anaplastic. Mutation of the p53 gene often results in a
stabilized protein of altered functionality that accumu-
lates in the nucleus of tumor cells [35]. Our data are thus
consistent with those recently reported by Frank and col-
leagues, who found that the TP53 pathway was frequently
disrupted in large cell/anaplastic medulloblastomas [9].
Interestingly, supratentorial PNET and ATRT were also
more commonly p53 immunopositive than non-anaplas-
tic medulloblastoma in our study. While extracerebellar
PNET were included in several earlier studies, p53 immu-
noreactivity was not reported separately for these lesions
[14,15]. Ho and colleagues documented p53 mutations in
6 of 14 sPNET but did not examine protein expression
[36]. In another relatively large series, only 1 of 12 sPNET
contained a mutation in the p53 gene [37]. Finally, Pos-
tovsky and colleagues described an unusual p53 mutation
in a case report of a sPNET [38]. With regard to rhabdoid
lesions, Berrak and colleagues documented faint p53
immunoreactivity in 6 of the 7 ATRT of the CNS they
examined [39]. Malignant rhabdoid tumors arising out-
side the CNS are also commonly p53 immunopositive,
and mutations predicted to inactivate p53 function have
been documented in some [40]. Thus while the number
of sPNET and ATRT we examined was relatively low, our
data, combined with earlier reports, suggests that p53
function may be commonly altered in embryonal tumors
arising outside the cerebellum.
Clinical outcomes were significantly worse for embryonal
brain tumor patients in our study whose lesions were p53
immunopositive. However, cases most commonly posi-
tive for p53 (anaplastic medulloblastomas, sPNET, and
ATRT) are all more clinically aggressive than non-anaplas-
tic medulloblastomas, making it difficult to infer causality
resulting from p53 accumulation. p53 expression did not
predict outcome within the group of medulloblastoma
patients, although all 3 strongly p53 immunopositive
tumors were severely anaplastic and associated with quite
short survival. Interestingly, in a recently published
report, Ray and colleagues found that p53 immunoreac-
tivity was the only biological marker predictive of poor
outcome on both univariate and multivariate analyses in
a group of 112 medulloblastoma patients [41].
Table 1: Intensity and extent of p53 immunopositivity in CNS 
embryonal tumors
Case Tumor Subtype p53 Intensity p53 Positive Cells
1 Classic MB 1 5 to 25%
2 Classic MB 1 5 to 25%
3 Classic MB 1 5 to 25%
4 Classic MB 1 5 to 25%
5 Classic MB 1 5 to 25%
6 Nodular MB 1 5 to 25%
7 Nodular MB 1 5 to 25%
8 Nodular MB 1 5 to 25%
9 Moderately Anaplastic MB 1 5 to 25%
10 Moderately Anaplastic MB 1 5 to 25%
11 Moderately Anaplastic MB 1 5 to 25%
12 Moderately Anaplastic MB 1 5 to 25%
13 Moderately Anaplastic MB 1 5 to 25%
14 Moderately Anaplastic MB 1 5 to 25%
15 Severely Anaplastic MB 2 51 to 75%
16 Severely Anaplastic MB 2 51 to 75%
17 Severely Anaplastic MB 2 26 to 50%
18 sPNET 1 5 to 25%
19 sPNET 1 5 to 25%
20 sPNET 1 5 to 25%
21 sPNET 2 5 to 25%
22 sPNET/Medulloepithelioma 1 5 to 25%
23A sPNET/Medulloepithelioma 2 51 to 75%
23B sPNET/Medulloepithelioma 2 76 to 100%
24 AT/RT 1 5 to 25%
25 AT/RT 2 26 to 50%
MB – medulloblastoma; sPNET – supratentorial PNET; AT/RT – 
atypical teratoid/rhabdoid tumor; p53 Intensity (0 – negative, 1 – 
weak, 2 – strong).BMC Cancer 2005, 5:19 http://www.biomedcentral.com/1471-2407/5/19
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We also examined the potential role of viral infection as a
mechanism for p53 protein stabilization in medulloblas-
toma. None of the four p53-positive cases from our tissue
array with frozen material available contained viral
sequences. We also tested nine additional samples of his-
tological subtypes that were more commonly associated
with p53 immunopositive staining (anaplastic medullob-
lastomas and sPNETs) where p53 staining was not per-
formed. None of these tumors were JCV positive. While
sample availability precluded complete testing of all con-
firmed p53 positive tumors for JCV, the available data do
not support a causal role for JCV infection in p53 accumu-
lation and development of embryonal brain tumors.
The impact of viruses on medulloblastoma pathogenesis
is controversial. The most commonly implicated agents
are the polyomavirus family members JC virus, BK virus
and SV40 virus. Of these, JC virus, which infects approxi-
mately 80% of the pediatric population and can cause
CNS disease in immunosuppressed patients, has been
most studied. It was shown decades ago that inoculation
of JC virus into rodents resulted in formation of medul-
loblastoma-like cerebellar tumors [20,22,42,43]. Trans-
genic mice containing JC virus early region sequences also
develop medulloblastomas [44]. Del Valle and colleagues
isolated JC virus large T antigen sequences from 11 of 23
human medulloblastomas they examined, and suggested
inactivation of p53 and Rb by viral T antigen could be
important in the pathogenesis of human embryonal brain
tumors [24]. A second gene (Agno) from JC virus was later
reported to be present in 11 of 16 medulloblastoma sam-
ples by the same group [25].
We failed to detect JC virus sequences in the 33 cases
examined, using a sensitive and specific technique which
should identify as few as 10 viral genomes per PCR reac-
JC virus sequences are not detected in embryonal brain tumors Figure 3
JC virus sequences are not detected in embryonal brain tumors. JC virus plasmid DNA is detectable over a wide 
range of dilutions when added to genomic DNA (A), but was not identified in DNA extracted from a range of embryonal brain 
tumors (B). In contrast, the ERV-3 endogenous retrovirus is easily detected both using standard dilution curves (C) and in 
tumor DNA (D).
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tion. This suggests the p53 immunopositivity we observe
is not caused by JC virus infection in the majority of cases.
Our data are also not consistent with the hypothesis that
ongoing JC virus infection is common in medulloblast-
oma. Other recent studies have also reported a lack of JC
virus DNA in medulloblastomas. Hayashi and colleagues
failed to identify JC viral sequences in 13
medulloblastomas [45]. Kim and colleagues similarly
failed to identify JC virus in 15 medulloblastomas, 5
sPNET and 2 medulloblastoma cell lines [46]. Rollison
and colleagues examined 225 brain tumors, including 20
medulloblastomas, for JC, BK and SV40 viruses at two dif-
ferent laboratories [47]. No tumor tested positive in both
laboratories. Finally, Weggen and colleagues failed to
detect JC virus sequences in any of 116 medulloblastomas
analyzed, although 2 of these cases were SV40 positive
[48]. These reports do not rule out the possibility of a "hit
and run" process in which virus participates initially in the
formation of a lesion and is then lost. They do strongly
suggest that ongoing JC virus infection is not common in
human medulloblastomas, as was initially suggested.
Interestingly, it has recently been shown that the putative
SV40 infection of human mesotheliomas can be
accounted for by contamination of samples with small
amounts of common laboratory plasmids containing
regions of the T-antigen gene [49], calling into question
the true association of SV40 with human cancers, includ-
ing brain tumors.
Conclusion
In summary, we find significantly increased p53 protein
levels in anaplastic medulloblastomas, sPNET, and ATRT
as compared to classic and nodular medulloblastoma. JC
virus was not detected in the 33 tumors examined, sug-
gesting that T-antigen binding does not appear to be an
ongoing factor in the pathobiology or p53 protein accu-
mulation of embryonal brain tumors.
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